JP2016138129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016138129A5 JP2016138129A5 JP2016078639A JP2016078639A JP2016138129A5 JP 2016138129 A5 JP2016138129 A5 JP 2016138129A5 JP 2016078639 A JP2016078639 A JP 2016078639A JP 2016078639 A JP2016078639 A JP 2016078639A JP 2016138129 A5 JP2016138129 A5 JP 2016138129A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fcγriib
- composition
- target cell
- antibody molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1013989.7 | 2010-08-20 | ||
| GBGB1013989.7A GB201013989D0 (en) | 2010-08-20 | 2010-08-20 | Biological materials and methods of using the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Division JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016138129A JP2016138129A (ja) | 2016-08-04 |
| JP2016138129A5 true JP2016138129A5 (enExample) | 2017-06-08 |
| JP6421140B2 JP6421140B2 (ja) | 2018-11-07 |
Family
ID=42984443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Active JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
| JP2016078639A Active JP6421140B2 (ja) | 2010-08-20 | 2016-04-11 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524483A Active JP6215704B2 (ja) | 2010-08-20 | 2011-08-19 | Ｆｃガンマｒｉｉｂ（ｃｄ３２ｂ）特異的抗体およびｃｄ２０特異的抗体の併用使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10525129B2 (enExample) |
| EP (2) | EP3263602A1 (enExample) |
| JP (2) | JP6215704B2 (enExample) |
| KR (1) | KR101948609B1 (enExample) |
| CN (8) | CN114099669A (enExample) |
| AU (1) | AU2011290503B2 (enExample) |
| CA (1) | CA2808744C (enExample) |
| DK (1) | DK2606068T3 (enExample) |
| ES (1) | ES2653685T3 (enExample) |
| GB (1) | GB201013989D0 (enExample) |
| HU (1) | HUE037478T2 (enExample) |
| NO (1) | NO2606068T3 (enExample) |
| PL (1) | PL2606068T3 (enExample) |
| PT (1) | PT2606068T (enExample) |
| RU (2) | RU2769949C2 (enExample) |
| SI (1) | SI2606068T1 (enExample) |
| WO (1) | WO2012022985A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201013989D0 (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| SG11201503719WA (en) * | 2012-11-29 | 2015-06-29 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC) |
| EP2740805B1 (en) * | 2012-12-07 | 2019-02-20 | SuppreMol GmbH | Stratification and treatment of patients suffering from idiopathic thrombocytopenic purpura |
| US10450354B2 (en) | 2013-03-12 | 2019-10-22 | Molecular Templates, Inc. | CD20-binding immunotoxins for inducing cellular internalization and methods using same |
| EP2833139A1 (en) * | 2013-08-01 | 2015-02-04 | SuppreMol GmbH | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) |
| IL285403B2 (en) | 2014-01-27 | 2023-10-01 | Molecular Templates Inc | Polypeptides that remove an epitope for MHC group I |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| GB2526139A (en) * | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| EP3137488B1 (en) | 2014-06-11 | 2019-01-02 | Molecular Templates, Inc. | Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same |
| KR20170110601A (ko) | 2015-02-05 | 2017-10-11 | 몰레큘러 템플레이츠, 인코퍼레이션. | 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물 |
| WO2016146702A1 (en) * | 2015-03-16 | 2016-09-22 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Trispecific binding molecules for treating hbv infection and associated conditions |
| HUE051246T2 (hu) | 2015-05-30 | 2021-03-01 | Molecular Templates Inc | Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák |
| CA3008102A1 (en) | 2015-12-18 | 2017-06-22 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| JP7075134B2 (ja) | 2016-12-07 | 2022-05-25 | モレキュラー テンプレーツ，インク． | 部位特異的コンジュゲーションのための志賀毒素ａサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子 |
| JP7082424B2 (ja) | 2017-01-25 | 2022-06-08 | モレキュラー テンプレーツ，インク． | 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子 |
| CN110536699A (zh) * | 2017-01-30 | 2019-12-03 | 俄亥俄州立创新基金会 | 被动抗体依赖性细胞介导的活化 |
| EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2018229706A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Combination therapy for the treatment of cancer |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| WO2019108900A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| KR20200143634A (ko) | 2018-04-17 | 2020-12-24 | 몰레큘러 템플레이츠, 인코퍼레이션. | 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자 |
| CN108823211A (zh) * | 2018-05-04 | 2018-11-16 | 中国医学科学院基础医学研究所 | 一种cd19核酸适配体及其应用 |
| AU2019277029C1 (en) | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| BR112022000755A2 (pt) * | 2019-07-17 | 2022-03-15 | Bioinvent Int Ab | Combinação, composição farmacêutica, kit para uso no tratamento de câncer, uso, método para o tratamento de câncer, e, teste diagnóstico para determinar se um paciente se beneficiará do tratamento |
| TW202122114A (zh) * | 2019-10-18 | 2021-06-16 | 美商建南德克公司 | 使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| EP3919077A1 (en) | 2020-06-04 | 2021-12-08 | BioInvent International AB | Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies |
| TW202210103A (zh) | 2020-06-04 | 2022-03-16 | 瑞典商生物創新國際有限公司 | 治療系統、方法及用途 |
| EP4240491A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19 binding molecules and uses thereof |
| TW202336033A (zh) | 2022-03-07 | 2023-09-16 | 瑞典商生物創新國際有限公司 | 抗體之新穎組合及用途 |
| WO2023201339A1 (en) | 2022-04-15 | 2023-10-19 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
| WO2023240064A1 (en) | 2022-06-08 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| ATE221379T1 (de) | 1991-05-01 | 2002-08-15 | Jackson H M Found Military Med | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| AU2063197A (en) | 1996-03-04 | 1997-09-22 | Massachusetts Institute Of Technology | Materials and methods for enhancing cellular internalization |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| ES2236832T3 (es) | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | Preparacion de particulas para inhalacion. |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2390412A1 (en) * | 1999-11-08 | 2001-05-17 | Idec Pharmaceuticals Corporation | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| WO2004016750A2 (en) | 2002-08-14 | 2004-02-26 | Macrogenics, Inc. | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| US20060177439A1 (en) | 2004-12-15 | 2006-08-10 | Scott Koenig | FcgammaRIIB-specific antibodies and methods of use thereof |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| WO2005018669A1 (en) | 2003-08-18 | 2005-03-03 | Macrogenics, Inc. | Fcϝriib-specific antibodies and methods of use thereof |
| US8853363B2 (en) | 2003-11-26 | 2014-10-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Substance binding human IgG Fc receptor IIb (FcγRIIb) |
| SG173322A1 (en) * | 2004-04-16 | 2011-08-29 | Macrogenics Inc Dw Us | Fc gammad riib - specific antibodies and methods of use thereof |
| CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB－特异性抗体及其使用方法 |
| JP2007536932A (ja) * | 2004-05-10 | 2007-12-20 | マクロジェニクス，インコーポレーテッド | ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| JP2008513351A (ja) * | 2004-05-20 | 2008-05-01 | セントメアリーズ ホスピタル エヌエイチエス トラスト | アレルギー疾患の処置のためのＩｇＥ再標的化機能変更分子（ＥＲＦＡＭ） |
| WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| EP1674479A1 (en) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation of Fc Gamma receptors for optimizing immunotherapy |
| CA2656224C (en) * | 2006-06-26 | 2018-01-09 | Macrogenics, Inc. | Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| WO2009062081A2 (en) | 2007-11-08 | 2009-05-14 | Pikamab, Inc. | Methods and compositions for antibody or vaccine therapy |
| EP2234641B1 (en) * | 2008-01-03 | 2015-08-19 | Genmab A/S | Monoclonal antibodies against cd32b |
| US20110268753A1 (en) | 2009-01-08 | 2011-11-03 | The Uab Research Foundation | Process for regulating immune response |
| GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
-
2010
- 2010-08-20 GB GBGB1013989.7A patent/GB201013989D0/en not_active Ceased
-
2011
- 2011-08-19 CN CN202110959481.9A patent/CN114099669A/zh active Pending
- 2011-08-19 CN CN202110959353.4A patent/CN114099667B/zh active Active
- 2011-08-19 CN CN202511469650.5A patent/CN121313820A/zh active Pending
- 2011-08-19 JP JP2013524483A patent/JP6215704B2/ja active Active
- 2011-08-19 PT PT117608190T patent/PT2606068T/pt unknown
- 2011-08-19 CA CA2808744A patent/CA2808744C/en active Active
- 2011-08-19 CN CN202110959352.XA patent/CN114099666B/zh active Active
- 2011-08-19 CN CN201710789909.3A patent/CN107670034B/zh active Active
- 2011-08-19 HU HUE11760819A patent/HUE037478T2/hu unknown
- 2011-08-19 US US13/817,744 patent/US10525129B2/en active Active
- 2011-08-19 EP EP17184259.4A patent/EP3263602A1/en not_active Withdrawn
- 2011-08-19 CN CN202110959354.9A patent/CN114099668B/zh active Active
- 2011-08-19 KR KR1020137006990A patent/KR101948609B1/ko active Active
- 2011-08-19 DK DK11760819.0T patent/DK2606068T3/da active
- 2011-08-19 NO NO11760819A patent/NO2606068T3/no unknown
- 2011-08-19 RU RU2017143633A patent/RU2769949C2/ru active
- 2011-08-19 PL PL11760819T patent/PL2606068T3/pl unknown
- 2011-08-19 AU AU2011290503A patent/AU2011290503B2/en active Active
- 2011-08-19 WO PCT/GB2011/051572 patent/WO2012022985A1/en not_active Ceased
- 2011-08-19 EP EP11760819.0A patent/EP2606068B1/en active Active
- 2011-08-19 RU RU2013112345/10A patent/RU2013112345A/ru unknown
- 2011-08-19 CN CN201180040351XA patent/CN103080131A/zh active Pending
- 2011-08-19 CN CN202110959355.3A patent/CN114099702B/zh active Active
- 2011-08-19 ES ES11760819.0T patent/ES2653685T3/es active Active
- 2011-08-19 SI SI201131366T patent/SI2606068T1/en unknown
-
2016
- 2016-04-11 JP JP2016078639A patent/JP6421140B2/ja active Active
-
2019
- 2019-11-14 US US16/684,450 patent/US11623005B2/en active Active
-
2021
- 2021-06-25 US US17/359,496 patent/US20210346498A1/en not_active Abandoned
-
2023
- 2023-03-01 US US18/177,050 patent/US12527866B2/en active Active
-
2025
- 2025-12-16 US US19/421,037 patent/US20260115286A1/en active Pending